Science Popularization
You are here: Home » Blogs » Science Popularization
Blogs In Science Popularization
  • 2026-07-21

    Hyaluronic acid vs sodium hyaluronate: same molecule, two acid–base states. Cut through 3 industry myths with CIR data, grade specs, and 6 sourcing questions.
  • 2026-07-21

    Sodium hyaluronate isn't one-size-fits-all for menopausal skin. Learn how multi-MW HA matrices, next-gen derivatives, and clinical evidence drive winning SKUs.
  • 2026-07-14

    Hyaluronic acid is becoming a platform, not an excipient. See 6 breakthroughs reshaping ophthalmic HA through 2030—cross-linked gels, injectables, and more.
  • 2026-07-14

    Artificial tears hit $2.8B in 2026 at 7.74% CAGR. See which ingredients are winning, how preservative-free is reshaping sourcing, and what B2B buyers plan next.
  • 2026-07-07

    Overview of Sterility Requirements for Ophthalmic Sodium Hyaluronate Sterility, bioburden, and endotoxin are distinct tests. Ophthalmic HA products require SAL 10⁻⁶, with limits varying by application (eye drops, OVDs, IOL coatings). Terminal sterilization methods (gamma, EO, heat) damage HA molecular weight. Therefore, sterility is typically achieved via aseptic processing and 0.22 µm filtration, supported by cleanroom controls and media fills. Raw material bioburden (USP <61>/<62>) should be low. EU GMP Annex 1 mandates a Contamination Control Strategy. Supplier audits should confirm aseptic environment, filter integrity testing, and compendial method validation.
  • 2026-07-07

    Overview of Endotoxin Control in Ophthalmic Sodium Hyaluronate Endotoxins (LPS) are heat-stable, filter-resistant bacterial cell-wall fragments that can persist in sterile products. In ophthalmic formulations, high viscosity prolongs tissue contact, amplifying response. Limits depend on application: raw material typically ≤0.05–0.5 EU/mg; OVDs and IOLs have finished-product limits per ISO 15798. Endotoxin enters via fermentation, water, resins, equipment, or packaging. Control requires WFI, validated depyrogenation, and cleanroom protocols. Testing HA requires validated spike recovery due to viscosity interference. Suppliers should specify LAL method, method validation, and rFC or MAT capabilities per evolving USP/EP/FDA standards.
  • Total 19 pages  Go to Page
  • Go
Shandong Runxin Biotechnology Co., Ltd. is a leading enterprise that has been deeply involved in the biomedical field for many years, integrating scientific research, production and sales.

Quick Links

Contact Us

  No.8 lndustrial park, Wucun Town, QuFu City, Shandong Province, China
  +86-532-6885-2019 / +86-537-3260902
   +86-13562721377
Send Us A Message
Copyright © 2024 Shandong Runxin Biotechnology Co., Ltd. All rights reserved.  Sitemap   Privacy Policy